Bingchen Yu

Bingchen Yu

Auto-generated profile, based on publicly available information

Bingchen Yu

Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JLJun Liu
Jun Liu
LCLi Cao
Li Cao
PKPaul C. Klauser
Paul C. Klauser
RCRujin Cheng
Rujin Cheng
VBViktoriya Y. Berdan
Viktoriya Y. Berdan
LWLei Wang
Lei Wang

7 June 2023 in ACS Central Science
Verified
Journal Article
Open access
PKPaul C. Klauser
Paul C. Klauser
SCShalini Chopra
Shalini Chopra
LCLi Cao
Li Cao
Kondapa Naidu BobbaKondapa Naidu Bobba
Kondapa Naidu Bobba
BYBingchen Yu
Bingchen Yu
LWLei Wang
Lei Wang
Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics to prolong circulation and normal tissue irradiation. Here we report the first covalent protein TRT, which, through reacting with the target irreversibly, increases radioactive dose to the tumor without altering the drug's pharmacokinetic profile or normal tissue biodistribution. Through genetic code expansion, we engineered a latent bioreactive amino acid into a nanobody, which binds to its target protein and forms a covalent linkage via the proximity-enabled reactivity, cross-linking the target irreversibly in vitro, on cancer cells, and on tumors in vivo. The radiolabeled covalent nanobody markedly increases radioisotope levels in tumors and extends tumor residence time while maintaining rapid systemic clearance. Furthermore, the covalent nanobody conjugated to the α-emitter actinium-225 inhibits tumor growth more effectively than the noncovalent nanobody without causing tissue toxicity. Shifting the protein-based TRT from noncovalent to covalent mode, this chemical strategy improves tumor responses to TRTs and can be readily scaled to diverse protein radiopharmaceuticals engaging broad tumor targets.

24 February 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SWSijie Wang
Sijie Wang
FFFranco F. Faucher
Franco F. Faucher
MBMatilde Bertolini
Matilde Bertolini
HKHeeyoung Kim
Heeyoung Kim
BYBingchen Yu
Bingchen Yu
MBMatthew Bogyo
Matthew Bogyo

20 June 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
BYBingchen Yu
Bingchen Yu
LCLi Cao
Li Cao
SLShanshan Li
Shanshan Li
PKPaul C. Klauser
Paul C. Klauser
LWLei Wang
Lei Wang
The proximity-enabled sulfur(VI) fluoride exchange (SuFEx) reaction generates specific covalent linkages between proteins in cells and in vivo, which opens innovative avenues for studying elusive protein–protein interactions and developing potent covalent protein drugs. To exploit the power and expand the applications of covalent proteins, covalent linkage formation between proteins is the critical step, for which fundamental kinetic and essential properties remain unexplored. Herein, we systematically studied SuFEx kinetics in different proteins and conditions. In contrast to in small molecules, SuFEx in interacting proteins conformed with a two-step mechanism involving noncovalent binding, followed by covalent bond formation, exhibiting nonlinear rate dependence on protein concentration. The protein SuFEx rate consistently changed with protein binding affinity as well as chemical reactivity of the functional group and was impacted by target residue identity and solution pH. In addition, kinetic analyses of nanobody SR4 binding with SARS-CoV-2 spike protein revealed that viral target mutations did not abolish covalent binding but decreased the SuFEx rate with affinity decrease. Moreover, off-target cross-linking of a SuFEx-capable nanobody in human serum was not detected, and the SuFEx-generated protein linkage was stable at cellular acidic pHs, suggesting SuFEx suitability for in vivo usage. These results advanced our understanding of SuFEx reactivity and kinetics in proteins, which is invaluable for ongoing exploration of SuFEx-enabled covalent proteins for basic biological research and creative biotherapeutics.

18 June 2024 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
LYLingyun Yang
Lingyun Yang
ZYZhengnan Yuan
Zhengnan Yuan
YLYongkuan Li
Yongkuan Li
SYShuyue Yang
Shuyue Yang
BYBingchen Yu
Bingchen Yu

22 August 2025 in Tetrahedron Chem
Verified
Journal Article
Open access
SYShuyue Yang
Shuyue Yang
YLYongkuan Li
Yongkuan Li
LYLingyun Yang
Lingyun Yang
BYBingchen Yu
Bingchen Yu